COVID-19 Clinical Trial Resumptions Slow as Cases Rise Again

Article

Clinical trials disrupted by COVID-19 are expected to resume at a much slower rate than originally anticipated, as more nations are re-enforcing lockdown due to a globally rising number of COVID-19 cases, says GlobalData.

Priya Nair, Trials Intelligence Analyst at GlobalData, commented, “The general trend shows a gradual increase in the overall percentage of trials for each trial status*, the biggest of which has been seen in trials that are ongoing and recruiting and those that are ongoing but not recruiting. Between August 17th and September 21st, ongoing and recruiting trials decreased from 84.7% to 82.2%, while completed trials increased from 4.5% to 6.4%.”

There is also an overall steady increase of trials resuming activity. The U.S. has the highest number of resumed trials at 70.6%, followed by France at 7.6%, the UK and Spain at 7%.

* Completed; Ongoing, not recruiting; Ongoing, recruiting; Planned

For more of their findings, click here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
Related Content
© 2024 MJH Life Sciences

All rights reserved.